TY - JOUR
T1 - Long-term efficacy of Narivent® in the treatment of nasal congestion
AU - Damiani, Valerio
AU - Camaioni, Angelo
AU - Viti, Claudio
AU - Schillani, Giulia
AU - Foltran, Francesca
AU - Scirè, Antonella Silvia
AU - Morpurgo, Giada
AU - Gregori, Dario
PY - 2012
Y1 - 2012
N2 - Rationale and aim: Nasal congestion is a common symptom in allergic and non-allergic rhinitis, rhinosinusitis and nasal polyposis. Although various pharmacotherapy options exist, no agent is universally efficacious. The aim of this study was to evaluate the clinical effectiveness efficacy of Narivent®, which is an osmotically acting medical device with anti-oedematous and anti-inflammatory effects, in a long-term (30 days) treatment. Methods: A single-centre prospective study with a pre-post design was conducted with consecutive enrolment in an Italian Otolaryngology Department of 56 both genders patients with persistent nasal congestion. Patients received 2 puffs of Narivent® into each nostril 2 times a day over the course of 4 weeks. The severity of symptoms was assessed subjectively as measured by a 0 to 10 visual analogue scale (VAS) and the presence/absence of symptoms and signs. Differences in subjective and objective severity measures before and after treatment were compared using Paired-Sample Wilcoxon Signed Rank Test. Results: A significant improvement after treatment (p
AB - Rationale and aim: Nasal congestion is a common symptom in allergic and non-allergic rhinitis, rhinosinusitis and nasal polyposis. Although various pharmacotherapy options exist, no agent is universally efficacious. The aim of this study was to evaluate the clinical effectiveness efficacy of Narivent®, which is an osmotically acting medical device with anti-oedematous and anti-inflammatory effects, in a long-term (30 days) treatment. Methods: A single-centre prospective study with a pre-post design was conducted with consecutive enrolment in an Italian Otolaryngology Department of 56 both genders patients with persistent nasal congestion. Patients received 2 puffs of Narivent® into each nostril 2 times a day over the course of 4 weeks. The severity of symptoms was assessed subjectively as measured by a 0 to 10 visual analogue scale (VAS) and the presence/absence of symptoms and signs. Differences in subjective and objective severity measures before and after treatment were compared using Paired-Sample Wilcoxon Signed Rank Test. Results: A significant improvement after treatment (p
KW - Anti-inflammatory activity
KW - Anti-oedematous activity
KW - Osmotically acting medical device
KW - Persistent nasal congestion
UR - http://www.scopus.com/inward/record.url?scp=84867566904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867566904&partnerID=8YFLogxK
U2 - 10.2174/1875181401204010073
DO - 10.2174/1875181401204010073
M3 - Article
AN - SCOPUS:84867566904
VL - 4
SP - 73
EP - 79
JO - Open Medical Devices Journal
JF - Open Medical Devices Journal
SN - 1875-1814
IS - SPL. ISS.
ER -